

<b>DATE:</b>	2021 December 29
<b>TO:</b>	All APL Clients
<b>FROM:</b>	Provincial Molecular Pathology Program
<b>RE:</b>	Changes to BCR/ABL1 Follow-Up (quantitative) and Diagnostic (qualitative) Test Directory Pages

---

## PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

---

### Key Message

- Effective immediately, the BCR/ABL1 Diagnostic and BCR/ABL1 Follow-up APL test directory pages have been merged into a single page named BCR/ABL1 t(9;22) Translocation

### Background

- Separate orders and test pages for BCR/ABL1 Diagnostic (Qualitative) and Follow-up (Quantitative) test have created confusion for the ordering, collection and testing
- This has also led to difficulty in resulting and reporting from EPIC/BEAKER.
- Combining the test directory pages will allow a single order to be placed in EPIC/BEAKER with the testing lab deciding on which test, qualitative or quantitative, is most appropriate for the patient based upon clinical history and previous testing

### How this will impact you

- Clients ordering BCR/ABL1 Diagnostic (qualitative) or Follow-up (quantitative) testing within the EPIC/BEAKER system:
  - Order BCR/ABL1 t(9;22) Translocation
- Clients ordering BCR/ABL1 outside of the EPIC/BEAKER system:
  - Continue to order and collect as indicated on the test directory page considering whether testing will be performed at Molecular Pathology, North or at Molecular Pathology (DSC), South.

### Action Required

- Follow direction provided by test directory page BCR/ABL1 t(9;22) Translocation when ordering, collecting and transporting samples for qualitative and quantitative BCR/ABL1 testing.

### Effective

- Immediately

### Questions/Concerns

- Dr. Faisal Khan, Scientific Lead, Molecular Pathology Program, South [Faisal.Khan@aplabs.ca](mailto:Faisal.Khan@aplabs.ca)
- Dr. Adrian Box, Medical Lead Molecular Pathology Program, South [Adrian.Box@aplabs.ca](mailto:Adrian.Box@aplabs.ca)
- Dr. Suofiane El-Hallani, Scientific Lead, Molecular Pathology Program, North [Soufiane.ElHallani@aplabs.ca](mailto:Soufiane.ElHallani@aplabs.ca)
- Dr. Cheryl Mather, Medical Lead Molecular Pathology Program, North [Cheryl.Mather@aplabs.ca](mailto:Cheryl.Mather@aplabs.ca)

### Approved by

- Dr. Adrian Box, Medical Lead Molecular Pathology Program, South [Adrian.Box@aplabs.ca](mailto:Adrian.Box@aplabs.ca)